Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIOL (Levofloxacin, Amoxicillin, Lansoprazole) for H. pylori Eradication
NCT01131026Phase 3Completed
- Sponsor
- Deva Pharmaceuticals
- Start
- Jun 2010
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of levofloxacin in Helicobacter pylori infection, sponsored by Deva Pharmaceuticals. Primary endpoint: Helicobacter pylori infection eradication at 6 weeks. Started Jun 2010; status: completed.
02
Drugs
levofloxacin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT01131026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01131026.